NasdaqGM:AGLE

Stock Analysis Report

Executive Summary

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer.

Snowflake

Fundamentals

Flawless balance sheet with moderate growth potential.

Share Price & News

How has Aeglea BioTherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.9%

NasdaqGM:AGLE

-0.2%

US Biotechs

-1.0%

US Market


1 Year Return

-14.1%

NasdaqGM:AGLE

-8.1%

US Biotechs

-0.4%

US Market

AGLE underperformed the Biotechs industry which returned -10% over the past year.

AGLE underperformed the Market in United States of America which returned -1.7% over the past year.


Share holder returns

AGLEIndustryMarket
7 Day0.9%-0.2%-1.0%
30 Day12.7%-0.2%-3.3%
90 Day21.9%2.4%0.4%
1 Year-14.1%-14.1%-7.3%-8.1%1.8%-0.4%
3 Year53.1%53.1%9.7%5.9%39.4%30.4%
5 Yearn/a7.8%2.8%54.2%37.1%

Price Volatility Vs. Market

How volatile is Aeglea BioTherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aeglea BioTherapeutics undervalued based on future cash flows and its price relative to the stock market?

2.29x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Aeglea BioTherapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Aeglea BioTherapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Aeglea BioTherapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Aeglea BioTherapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Aeglea BioTherapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Aeglea BioTherapeutics is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Aeglea BioTherapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

10.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Aeglea BioTherapeutics's revenue is expected to grow significantly at over 20% yearly.

Aeglea BioTherapeutics's earnings are expected to grow by 10.8% yearly, however this is not considered high growth (20% yearly).

Aeglea BioTherapeutics's revenue growth is expected to exceed the United States of America market average.

Aeglea BioTherapeutics's earnings growth is positive but not above the United States of America market average.

Aeglea BioTherapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Aeglea BioTherapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Aeglea BioTherapeutics performed over the past 5 years?

-38.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Aeglea BioTherapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Aeglea BioTherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Aeglea BioTherapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Aeglea BioTherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Aeglea BioTherapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Aeglea BioTherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Aeglea BioTherapeutics's financial position?


Financial Position Analysis

Aeglea BioTherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Aeglea BioTherapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Aeglea BioTherapeutics has no debt.

Aeglea BioTherapeutics has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Aeglea BioTherapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Aeglea BioTherapeutics has sufficient cash runway for 2.2 years based on current free cash flow.

Aeglea BioTherapeutics has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 36.1% each year.


Next Steps

Dividend

What is Aeglea BioTherapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Aeglea BioTherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Aeglea BioTherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Aeglea BioTherapeutics has not reported any payouts.

Unable to verify if Aeglea BioTherapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Aeglea BioTherapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Aeglea BioTherapeutics's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Anthony Quinn (57yo)

2.1yrs

Tenure

US$3,842,134

Compensation

Dr. Anthony G. Quinn, M.B Ch.B., Ph.D., FRCP, has been President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. since July 19, 2018 and its Director since 2016. Dr. Quinn serves as a Director  ...


CEO Compensation Analysis

Anthony's remuneration is higher than average for companies of similar size in United States of America.

Anthony's compensation has increased whilst company is loss making.


Management Age and Tenure

2.3yrs

Average Tenure

53yo

Average Age

The tenure for the Aeglea BioTherapeutics management team is about average.


Board Age and Tenure

2.9yrs

Average Tenure

56yo

Average Age

The average tenure for the Aeglea BioTherapeutics board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Aeglea BioTherapeutics individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$196,45314 Jun 19
Anthony Quinn
EntityIndividual
Role
President
Member of the Board of Directors
Shares31,905
Max PriceUS$6.23
BuyUS$180,03222 May 19
Anthony Quinn
EntityIndividual
Role
President
Member of the Board of Directors
Shares26,592
Max PriceUS$6.89
BuyUS$5,10317 May 19
Anthony Quinn
EntityIndividual
Role
President
Member of the Board of Directors
Shares719
Max PriceUS$7.10
BuyUS$121,29517 May 19
Anthony Quinn
EntityIndividual
Role
President
Member of the Board of Directors
Shares17,994
Max PriceUS$6.83
SellUS$57,00528 Sep 18
Aaron Schuchart
EntityIndividual
Role
Chief Business Officer
Shares6,000
Max PriceUS$9.55

Ownership Breakdown


Management Team

  • F. Dorr (66yo)

    Executive Officer

    • Tenure: 2.3yrs
  • Aaron Schuchart (54yo)

    Chief Business Officer

    • Tenure: 2.3yrs
  • Anthony Quinn (57yo)

    President

    • Tenure: 2.1yrs
    • Compensation: $3.84m
  • Scott Rowlinson (51yo)

    Vice President of Research

    • Tenure: 5.5yrs
    • Compensation: $607.53k
  • Charles York (42yo)

    CFO & VP

    • Tenure: 3.9yrs
    • Compensation: $960.82k
  • Eugene Sackett

    Vice President of Human Resources

  • Jim Wooldridge (53yo)

    Chief Medical Officer

    • Tenure: 2.1yrs
    • Compensation: $744.01k
  • Leslie Sloan (48yo)

    Chief Operating Officer

    • Tenure: 2.0yrs

Board Members

  • Russ Cox (56yo)

    Chairman of the Board

    • Tenure: 0.6yrs
    • Compensation: $179.26k
  • Anthony Quinn (57yo)

    President

    • Tenure: 3.4yrs
    • Compensation: $3.84m
  • Sue Bruhn (56yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: $180.59k
  • Wayne Klohs

    Member of Scientific Advisory Board

    • Tenure: 2.9yrs
  • Arthur Frankel

    Member of Scientific Advisory Board

    • Tenure: 2.9yrs
  • Sandy Mahatme (54yo)

    Director

    • Tenure: 4.2yrs
    • Compensation: $187.59k
  • Matthew Vander Heiden

    Member of Scientific Advisory Board

    • Tenure: 2.9yrs
  • Keith Flaherty (48yo)

    Member of Scientific Advisory Board

    • Tenure: 2.9yrs
  • Dan Von Hoff (71yo)

    Member of Scientific Advisory Board

    • Tenure: 2.9yrs
  • Armen Shanafelt (60yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: $211.09k

Company Information

Aeglea BioTherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aeglea BioTherapeutics, Inc.
  • Ticker: AGLE
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$228.195m
  • Shares outstanding: 28.89m
  • Website: Click here

Number of Employees


Location

  • Aeglea BioTherapeutics, Inc.
  • Barton Oaks Plaza One
  • Suite 250
  • Austin
  • Texas
  • 78746
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGLENasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 2016

Biography

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company’s lead  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 01:04
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.